You are viewing a preview of...
Novel Toll-Like Receptor (TLR) 7/8 Agonist Antibody-Drug Conjugates
Antibody-drug conjugates of novel increased-potency TLR 7/8 agonists

Background
Toll-like receptor (TLR) agonists are immunostimulants that are often used as vaccine adjuvants. They activate the adaptive immune system leading to a more robust antiviral effect, and can also be used to unmask the immunosuppressive tumor environment and initiate a robust anti‐tumor response by the immune system. A number of TLR 7/8 agonists have been developed for anticancer and antiviral applications, including the approved compound imiquimod.
Technology Overview
A current limitation of TLR agonist use is that their systemic delivery can result in whole‐body immunostimulation, leading to acute toxicity from a cytokine‐storm event. To circumvent this, Binghamton University researchers have developed antibody-drug conjugates (ADCs) of TLR 7/8 agonists for targeting select tumor cells. Specifically, they have developed novel TLR
Log in or create a free account to continue reading